Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
ENGN

enGene Therapeutics (ENGN) stock: insider trades, news & valuation

Health Care · Net buying
Close · Oct 9, 2026 $1.73 -2.8% on the day -80.5% over 12 months 52-week range $1.44 – $12.17

Share price and insider trades

ENGN closeInsider buyInsider sale
051015NovDecJan 2026FebMarAprMayJunJulAugSepOctBought $10,051 on 2026-09-22 · William Grossman
Bought, 12 months$10K
Sold, 12 months$0
Insiders buying1
Insiders selling0

enGene Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $10K and 0 sold $0 of ENGN stock on the open market.

ENGN insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q3 2026: $10K bought (1 trades)$10KQ3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026$10K1—0

Valuation, profit and volume

P/E (trailing)n/aSector median 24.7
Market value$116MBiotechnology
Profit margin0.0%Revenue growth —
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit−$1KOn all tracked purchases -12.2%

Summary

Over the past 12 months, 1 enGene Therapeutics Inc. insider reported open-market purchases totaling $10K, while 0 insiders reported sales totaling $0.

ENGN stock news and SEC filings

Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Sep 24SEC William GrossmanInterim Chief Medical Officer Buy 5,102new position $1.97 $10K -12.2% —

Insiders at enGene Therapeutics Inc.

InsiderBoughtSoldLast filingScore
William GrossmanInterim Chief Medical Officer $10K — Sep 24, 2026 —

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • SLBTSL Science Holding Ltd$10329.90B bought
  • KODKodiak Sciences Inc.$157M bought
  • ADRXADARx Pharmaceuticals, Inc.$87.7M bought
  • ATTOAttovia Therapeutics, Inc.$72.9M bought
  • MPLTMapLight Therapeutics, Inc.$65.5M bought
  • AVRAnteris Technologies Global Corp.$40.4M bought

ENGN stock: common questions

Are enGene Therapeutics Inc. insiders buying ENGN stock?

In the past 12 months, 1 insiders reported open-market purchases of ENGN worth $10K. The latest was Interim Chief Medical Officer William Grossman bought $10K of ENGN at $1.97 — first open-market purchase in our records; opens a new position.

Are enGene Therapeutics Inc. insiders selling ENGN stock?

0 insiders reported sales worth $0 over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is ENGN's 52-week range?

Over the past year ENGN has traded between $1.44 and $12.17. It last closed at $1.73 on Oct 9, 2026.